Most Read Articles
Naomi Rodrig, 27 Apr 2016

LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]

Naomi Rodrig, 28 Apr 2016
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Pearl Toh, 13 May 2017
Short-term use of oral corticosteroids was associated with increased risks of adverse events such as fracture, sepsis, and venous thromboembolism (VTE), a large US cohort study showed.
Naomi Rodrig, 03 May 2016
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.

New Product Highlight - Nicorette

22 Jun 2015
NICORETTE – Nicotine 10 mg, 15 mg, 25 mg Patch
• Week 1 abstinence is an important predictor of long-term success1,3
• Significantly more smokers were abstinent during week 1 with Nicorette patch 25 mg/16 hr compared to our previous patch programme (p<0.01)2
• 94% more effective than placebo at helping smokers to quit at 12 weeks (p<0.001)1,5
• 44% more effective at helping smokers quit compared with our previous patch programme at 12 weeks (p<0.005)1,4
• 16-hr patch is well tolerated with a good safety profile6

References:
1. Tønnesen P et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Eur Resp J 1999;13:238-246
2. Data on file – CEASE 2.
3. Stapleton JA et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995;90:31–42.
4. Data on file – CEASE 3.
5. Data on file - CEASE 4.
6. Nicorette Invisi Transdermal Patch Package Insert 2014

Further information available in Section 18b, New in This Issue and mims.com. Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 27 Apr 2016

LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]

Naomi Rodrig, 28 Apr 2016
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Pearl Toh, 13 May 2017
Short-term use of oral corticosteroids was associated with increased risks of adverse events such as fracture, sepsis, and venous thromboembolism (VTE), a large US cohort study showed.
Naomi Rodrig, 03 May 2016
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.